Literature DB >> 20563845

Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial.

Jan Krhut1, Peter Zvara.   

Abstract

AIM: The objectives of this study were to compare the urodynamic effects of botulinum toxin A (BoNT-A) delivered via intramural injection into the bladder wall to that of intravesical instillation in a rat model of detrusor overactivity and to evaluate the effects of intravesical instillation of BoNT-A in female patients with idiopathic overactive bladder.
MATERIALS AND METHODS: Detrusor overactivity was induced in female Wistar rats using partial bladder outflow obstruction. Animals were treated with 5 units (U) of BoNT-A via intramural bladder injection (n = 6) or intravesical instillation (n = 7). Conscious cystometrograms were performed prior to BoNT-A administration and then repeated 7 days and 2 weeks following treatment. In the subsequent pilot clinical study, 16 female patients with overactive bladder refractory to antimuscarinics were treated with 200 units of BoNT-A in 50 mL of 0.9% saline instilled using a 12-F urethral catheter. Treatment outcome was evaluated immediately prior to and 1 month after BoNT-A administration.
RESULTS: In the preclinical study, the average intermicturition and threshold pressures, as well as the number and amplitude of non-voiding bladder contractions, decreased significantly in both instillation and injection groups. Micturition pressure decreased significantly only in the intramural injection group. In the pilot clinical study, seven patients reported improvement in symptoms. The average number of incontinence episodes was significantly reduced, and the volume at which the first non-voiding contraction was recorded increased by 52.8%.
CONCLUSION: The results of our urodynamic studies support the hypothesis that BoNT-A instilled into the urinary bladder affects bladder sensation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20563845     DOI: 10.1007/s11255-010-9790-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  32 in total

1.  Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study.

Authors:  Antonella Giannantoni; Elisabetta Costantini; Savino M Di Stasi; Maria Cristina Tascini; Vittorio Bini; Massimo Porena
Journal:  Eur Urol       Date:  2006-01-04       Impact factor: 20.096

2.  Botulinum toxin: historical perspective and potential new indications.

Authors:  J Jankovic; M F Brin
Journal:  Muscle Nerve Suppl       Date:  1997

3.  Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.

Authors:  B Schurch; M Stöhrer; G Kramer; D M Schmid; G Gaul; D Hauri
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

4.  Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.

Authors:  Ibrahim Fathi Ghalayini; Mohammed A Al-Ghazo; Ziad Ali Elnasser
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

5.  Topical oxybutynin chloride for relaxation of dysfunctional bladders.

Authors:  C B Brendler; L C Radebaugh; J L Mohler
Journal:  J Urol       Date:  1989-06       Impact factor: 7.450

6.  Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes.

Authors:  Yao-Chi Chuang; Pradeep Tyagi; Chao-Cheng Huang; Naoki Yoshimura; Moya Wu; Jonathan Kaufman; Michael B Chancellor
Journal:  J Urol       Date:  2009-06-18       Impact factor: 7.450

7.  Differential expression of bladder neurotrophic factor mRNA in male and female rats after bladder outflow obstruction.

Authors:  Peter Zvara; Jan Kliment; Anthony L DeRoss; Brian H Irwin; Susan E Malley; Mark K Plante; Margaret A Vizzard
Journal:  J Urol       Date:  2002-12       Impact factor: 7.450

Review 8.  Emerging role of botulinum toxin in the management of voiding dysfunction.

Authors:  Christopher P Smith; Michael B Chancellor
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

9.  The ultrastructure of bladder lamina propria nerves in healthy subjects and patients with detrusor hyperreflexia.

Authors:  Oliver J Wiseman; Ciaran M Brady; Iqbal F Hussain; Prokar Dasgupta; Hilary Watt; Clare J Fowler; David N Landon
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

Review 10.  The use of botulinum neurotoxin type A (BoNTA) in urology.

Authors:  A Apostolidis; C J Fowler
Journal:  J Neural Transm (Vienna)       Date:  2008-03-06       Impact factor: 3.575

View more
  6 in total

1.  Incontinence: should we inject the trigone during botulinum toxin injection?

Authors:  Arun Sahai; Prokar Dasgupta
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

Review 2.  Models of inflammation of the lower urinary tract.

Authors:  Dale E Bjorling; Zun-Yi Wang; Wade Bushman
Journal:  Neurourol Urodyn       Date:  2011-06       Impact factor: 2.696

Review 3.  Medical Management of Neurogenic Bladder for Children and Adults: A Review.

Authors:  Elizabeth Lucas
Journal:  Top Spinal Cord Inj Rehabil       Date:  2019

Review 4.  Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis.

Authors:  Wei Zhang; Xiaojing Deng; Chunyu Liu; Xu Wang
Journal:  Int Urogynecol J       Date:  2016-09-10       Impact factor: 2.894

5.  Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex.

Authors:  Xin Su; Angela Nickles; Dwight E Nelson
Journal:  BMC Urol       Date:  2015-06-09       Impact factor: 2.264

Review 6.  BoNT/A in the Urinary Bladder-More to the Story than Silencing of Cholinergic Nerves.

Authors:  Hodan Ibrahim; Jacquie Maignel; Fraser Hornby; Donna Daly; Matthew Beard
Journal:  Toxins (Basel)       Date:  2022-01-12       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.